SNO 2026
By Buzzbox Media · Last reviewed August 3, 2026
What is SNO?
SNO concentrates the entire brain tumor treatment community in one room, neurosurgeons, radiation oncologists, medical oncologists, and researchers. If you have a device or therapy used in neuro-oncology, there is no more targeted audience. The convention center venue in Philadelphia allows proper exhibit builds.
What are the key facts about SNO?
- Host organization: Society for Neuro-Oncology
- Primary specialty: neuro-oncology
- Scale: mid
- Geography: US
- International attendance: ~25%
- See all Neurology & Neurosurgery conferences
Which device categories fit SNO?
Which buyer stages does SNO fit?
What does SNO charge for booth space?
Cost not published
Society for Neuro-Oncology does not publish booth pricing for SNO that we can link to, so we do not list a figure here. We would rather show nothing than an estimate you cannot check. Ask them directly on the SNO exhibitor page ↗.
Planning the SNO booth itself? Read our guide to medical conference booth design for booth types, union labor rules, and the corner upgrade.
Who attends SNO?
Highly specialized audience focused exclusively on brain and CNS tumors. Mix of neurosurgeons, radiation oncologists, medical oncologists, neuropathologists, and researchers. The meeting is heavily science-driven with emphasis on clinical trials and translational research. Pharma presence is strong.
- Purchasing authority: ~55% of attendees
- Effective buyers: ~1,650
- International attendance: ~25%
Where is SNO held?
- Venue: Pennsylvania Convention Center, Philadelphia, PA
- Management company: SNO (in-house)
Who else exhibits at SNO?
Exhibitor data coming soon for SNO.
Is SNO worth exhibiting?
Why Exhibit
SNO concentrates the entire brain tumor treatment community in one room, neurosurgeons, radiation oncologists, medical oncologists, and researchers. If you have a device or therapy used in neuro-oncology, there is no more targeted audience. The convention center venue in Philadelphia allows proper exhibit builds.
Why Skip
Extremely narrow audience: if your product is not directly used in brain/CNS tumor treatment, this is not your show. The meeting is heavily science and pharma-driven, so pure device companies may feel out of place. Limited to ~3,000 attendees, so volume is modest. Pricing is not publicly listed.
What should exhibitors know before SNO?
Niche show with a niche audience. If brain tumors are your market, this is essential. If not, skip entirely. Pharma dominates the floor, so device companies need strong clinical data to compete for attention.
What is the Buzzbox Score for SNO?
7.0 / 10 (Strong)
7.0 out of 10. A solid, dependable show for the right exhibitor. Carried by exhibitor experience (7.7: society-run exhibits (in-house), non-union venue (simpler, cheaper move-in), and purpose-built convention venue). The lightest dimension is data transparency (7.0, ). SNO concentrates the entire brain tumor treatment community in one room, neurosurgeons, radiation oncologists, medical oncologists, and researchers.
How we score
Six weighted factors, each scored on a 0 to 100 rubric then normalized to a 7.0 to 10.0 band. Every show on this list cleared a relevance bar to be included, so 7.0 is the floor; the number tells you how far the leaders pull ahead. A factor we cannot source is left unscored rather than estimated, and the overall score above was set before any figure behind it was withdrawn.
Solid (7.4): 55% purchasing authority.
Not scored on cost: this organizer publishes no booth price we can link to.
Solid (7.0): attendee purchasing-authority data published, and all-in cost estimate available.
Solid (7.7): society-run exhibits (in-house), non-union venue (simpler, cheaper move-in), and purpose-built convention venue.
Solid (7.3): solid exhibitor rationale, honest "who should skip" guidance, and broad device-category relevance.
Solid (7.4): mid-size with room to grow.
When are the SNO exhibitor deadlines?
Detailed deadlines not yet published for SNO. Check the official site for the application window.
Frequently Asked Questions
How much does a booth cost at SNO?
SNO does not publish booth pricing we can link to, so we do not list a cost for this show. Rather than estimate one, we point you at the organizer's exhibitor page to request current rates directly.
How many people attend SNO?
SNO draws approximately 3,000 attendees. Highly specialized audience focused exclusively on brain and CNS tumors. Mix of neurosurgeons, radiation oncologists, medical oncologists, neuropathologists, and researchers. The meeting is heavily science-driven with emphasis on clinical trials and translational research. Pharma presence is strong.
When and where is SNO 2026?
SNO 2026 takes place November 12-15, 2026. The venue is Pennsylvania Convention Center, Philadelphia, PA. Society for Neuro-Oncology hosts the meeting.
How many SNO attendees have purchasing authority?
About 55% of SNO attendees hold purchasing authority, which works out to roughly 1,650 effective buyers out of approximately 3,000 attendees. Effective buyers multiplies total attendance by the share of attendees who hold purchasing authority. Both inputs are estimates drawn from organizer reporting and our own exhibitor research, so read the figure as directional rather than exact.
How does Buzzbox Media score SNO?
SNO carries a Buzzbox Score of 7.0 out of 10 (Strong), with one caveat on this record: cost efficiency is not scored, because Society for Neuro-Oncology publishes no booth price we can link to, and the overall score was set before that figure was withdrawn. The factors still scored are audience quality, data transparency, exhibitor experience, editorial value, and growth trajectory. Each factor is scored on a 0 to 100 rubric then normalized to a 7.0 to 10.0 band, and every conference in our index cleared a relevance bar to be listed, so 7.0 is the floor. On this record the highest is exhibitor experience at 7.7 and the lowest is data transparency at 7.0.
Who attends the SNO Annual Meeting?
SNO draws approximately 3,000 neuro-oncology specialists including neurosurgeons, radiation oncologists, medical oncologists, neuro-radiologists, and tumor board members focused on brain and spinal cancers. About 55% have direct purchasing authority.
What products are a good fit for SNO exhibitors?
SNO is best suited for neurosurgical navigation systems, intraoperative imaging equipment, radiation therapy devices, brain tumor biomarkers/diagnostics, and temozolomide or immunotherapy delivery platforms targeting CNS oncology.
Is SNO 2026 mostly a pharma meeting, or do medical device companies exhibit too?
Pharma and biotech companies dominate the SNO exhibit floor, and the program is heavily science and clinical-trial driven. Device companies do exhibit, especially in neuronavigation, intraoperative imaging, and radiation therapy, but they need strong clinical data to compete for attention alongside pharma.